Angelica Diez-Ferrando

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.

Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.

Journal: Clinical and translational medicine

Published: May 20, 2025

Comprehensive Clinical Characterization and Long-Term Follow-Up of the Institut Català d'Oncologia Breast Cancer Observational Cohort Study.

Comprehensive Clinical Characterization and Long-Term Follow-Up of the Institut Català d'Oncologia Breast Cancer Observational Cohort Study.

Journal: Cancers

Published: January 25, 2025

Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Journal: International journal of molecular sciences

Published: September 17, 2024

Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.

Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.

Journal: Therapeutic advances in medical oncology

Published: July 13, 2024

Salvage chemotherapy after progression on immunotherapy in recurrent/metastatic squamous cell head and neck carcinoma.

Salvage chemotherapy after progression on immunotherapy in recurrent/metastatic squamous cell head and neck carcinoma.

Journal: Frontiers in oncology

Published: July 02, 2024

Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel-plus-cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel-plus-cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Journal: Head & neck

Published: April 08, 2024

Assessing the reduction of viral infectivity in HPV16/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol.

Assessing the reduction of viral infectivity in HPV16/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol.

Journal: PloS one

Published: January 10, 2024

SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.

SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: August 07, 2023

How to prevent human papillomavirus-related oropharyngeal cancer?

How to prevent human papillomavirus-related oropharyngeal cancer?

Journal: Current opinion in oncology

Published: March 26, 2023

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer.

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer.

Journal: Cancers

Published: June 08, 2022

Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data.

Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data.

Journal: Breast (Edinburgh, Scotland)

Published: November 17, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026